TDM is dead. Long live TCI!

Twenty years ago, target concentration intervention (TCI) was distinguished from therapeutic drug monitoring (TDM). It was proposed that TCI would bring more clinical benefit because of the precision of the approach and the ability to link TCI to principles of pharmacokinetics and pharmacodynamics t...

Descripción completa

Detalles Bibliográficos
Autores principales: Holford, Nick, Ma, Guangda, Metz, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Pharmacometrics: Past, Present and Future ‐ Themed Issue Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290673/
https://www.ncbi.nlm.nih.gov/pubmed/32543717
http://dx.doi.org/10.1111/bcp.14434
_version_ 1784748958307844096
author Holford, Nick
Ma, Guangda
Metz, David
author_facet Holford, Nick
Ma, Guangda
Metz, David
author_sort Holford, Nick
collection PubMed
description Twenty years ago, target concentration intervention (TCI) was distinguished from therapeutic drug monitoring (TDM). It was proposed that TCI would bring more clinical benefit because of the precision of the approach and the ability to link TCI to principles of pharmacokinetics and pharmacodynamics to predict the dose required by an individual (1). We examine the theory and clinical trial evidence supporting the benefits of TCI over TDM and conclude that in the digital age TDM should be abandoned and replaced by TCI.
format Online
Article
Text
id pubmed-9290673
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92906732022-07-20 TDM is dead. Long live TCI! Holford, Nick Ma, Guangda Metz, David Br J Clin Pharmacol Pharmacometrics: Past, Present and Future ‐ Themed Issue Reviews Twenty years ago, target concentration intervention (TCI) was distinguished from therapeutic drug monitoring (TDM). It was proposed that TCI would bring more clinical benefit because of the precision of the approach and the ability to link TCI to principles of pharmacokinetics and pharmacodynamics to predict the dose required by an individual (1). We examine the theory and clinical trial evidence supporting the benefits of TCI over TDM and conclude that in the digital age TDM should be abandoned and replaced by TCI. John Wiley and Sons Inc. 2020-07-01 2022-04 /pmc/articles/PMC9290673/ /pubmed/32543717 http://dx.doi.org/10.1111/bcp.14434 Text en © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Pharmacometrics: Past, Present and Future ‐ Themed Issue Reviews
Holford, Nick
Ma, Guangda
Metz, David
TDM is dead. Long live TCI!
title TDM is dead. Long live TCI!
title_full TDM is dead. Long live TCI!
title_fullStr TDM is dead. Long live TCI!
title_full_unstemmed TDM is dead. Long live TCI!
title_short TDM is dead. Long live TCI!
title_sort tdm is dead. long live tci!
topic Pharmacometrics: Past, Present and Future ‐ Themed Issue Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290673/
https://www.ncbi.nlm.nih.gov/pubmed/32543717
http://dx.doi.org/10.1111/bcp.14434
work_keys_str_mv AT holfordnick tdmisdeadlonglivetci
AT maguangda tdmisdeadlonglivetci
AT metzdavid tdmisdeadlonglivetci

Ejemplares similares